206 articles in this topic
New research reveals how removing ZFP148 protein boosts CD8+ T cells' cancer-fighting ability and improves immunotherapy response.
New research reveals how our body clock regulates immune cell function through DNA modifications, offering insights for health optimization.
International research shows axial involvement in psoriatic arthritis is more common than previously thought, impacting treatment decisions.
Discover how persistent low-grade inflammation drives the aging process and learn strategies to combat this silent threat to longevity.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Small NIH study tests oral drug tofacitinib as potential new treatment for systemic lupus erythematosus with fewer side effects.
Small study tests whether tocilizumab can achieve faster, deeper remission in newly diagnosed rheumatoid arthritis patients.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
Phase 3 trial tests otilimab against standard care in 550 patients who failed previous biologics and JAK inhibitors.
Small study explores how tofacitinib may address chronic pain that persists even when inflammation is controlled in RA patients.
Researchers used blood biomarkers and machine learning to predict which expensive RA treatments work best for individual patients.
NYU study reveals how targeted immune therapy transforms inflammatory responses in rheumatoid arthritis treatment.
